Professor Lewis appeared on SftPublic's Contemporary Science Issues and Innovations March 24, 2015 to discuss his recent Breakthrough in Antibiotics Resistance. This breakthrough has received a great deal of attention in the medical community as well as in the media. Dr. Lewis explained the current crisis in antibiotics, by which bacterial resistance to antibiotics has accelerated. The method he and his colleagues pioneered has produced a new antibiotic, teixobactin, which at the time of this program was in the early stages of testing, but already making headlines.
Dr. Lewis is a permanent member of the Drug Discovery and Drug Resistance NIH Study Section, and has been Chair of two NIH Study Sections on Drug Discovery. He is a member of Faculty 1000, a world-wide panel of experts evaluating research advancements. He served as a panelist and contributor to the National Academies Institute of Medicine reports on antibiotic resistance in 2010 and 2011. His awards include the MIT C.E. Reed Faculty Initiative Award for an innovative research project (1992) and the NIH Director's Transformative Award (2009). Dr. Lewis is also founder of two Biotech Companies, NovoBiotic Pharmaceuticals, and Arietis Corporation.